Cerner names new chief technology officer

Jerome Labat has been hired as Cerner Corporation’s new chief technology officer.

Labat has more than 30 years of experience in technology and product development leadership at Fortune 500 companies and comes to Cerner from HPE Software, where he served as CTO and led the automation business. He also served as vice president of infrastructure automation and development operations at Oracle for 20 years.

At Missouri-based Cerner, Labat will aim to strengthen the company’s technology focus and accelerate cloud-enabled SaaS platforms and solutions. Cerner is one of the nation’s biggest EHR and health IT companies.

“Jerome’s deep technology expertise, global management experience and technical depth makes him an excellent fit for Cerner,” Cerner CEO and Chairman Brent Shafer said in a statement. “His background directly aligns with key priorities including delivering Cerner’s next-generation cognitive platform and accelerating the speed of Cerner’s technological innovations that meaningfully benefit our clients around the globe.”

Labat has also been issued six patents in the U.S. for software and technology advancements, while Cerner was issued its 500th patent last year.

“The span of my entire career has prepared me for this role­­––from building software and clients’ implementations to taking products to the cloud,” Labat said in a statement. “I now have the opportunity to help shape tomorrow’s health care which is something I’m passionate about.”

Labat’s hiring comes after Cerner named two new executive hires in February this year, including Don Trigg as president of the company and John Peterzalek as chief client and services officer.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.